Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 101, Issue , 2016, Pages 75-85

  Abdel Rahman, Omar ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Nivolumab; NSCLC; PD 1; PD L1; Pembrolizumab

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DOCETAXEL; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; TAXOID;

HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; METABOLISM; TREATMENT OUTCOME;

ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84959865025     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.03.007     Document Type: Review

References (33)

1. Abdel-Rahman O., Elhalawani H. Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis. Future Oncol. 2015, 11(7):1109-1122.
2. Abdel-Rahman O., ElHalawani H., Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 2015, 1-14.
3. Abdel-Rahman O., ElHalawani H., Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin. Drug Saf. 2015, 14(10):1507-1518.
4. Abdel-Rahman O., ElHalawani H., Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors; a Meta-analysis. Immunotherapy 2015.
5. Abdel-Rahman O., ElHalawani H., Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors; a meta-analysis. Future Oncol. 2015.
6. Abdel-Rahman O., Ahmed H., Elhalawani H. Risk of elevated transaminases in non small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib; a Meta analysis. Expert Rev. Respir. Med. 2016, 10(2):223-234.
7. Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit. Rev. Oncol. Hematol. 2015.
8. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann. Oncol. 2014, 25(10):1935-1940.
9. Besse B., Johnson M., Jaenne P., Garassino M., Eberhardt W., Peters S., et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur. J. Cancer 2015, (ELSEVIER SCI LTD THE BOULEVARD, LANGFORD, LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND).
10. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373(17):1627-1639.
11. Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W.E.E., Poddubskaya E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 2015.
12. Carbognin L., Pilotto S., Milella M., Vaccaro V., Brunelli M., Caliò A., et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 2015, 10(6):e0130142.
13. Collins L.G., Haines C., Perkel R., Enck R.E. Lung cancer: diagnosis and management. Am. Fam. Phys. 2007, 75(1):56-63.
14. Gainor J.F., Sequist L.V., Shaw A.T., Azzoli C.G., Piotrowska Z., Huynh T., et al. Clinical correlation and frequency of programmed death ligand-1 (PD-L1) expression in EGFR-mutant and ALK-rearranged non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings 2015.
15. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian A.S., Eder J.P., et al. Pembrolizumab for the treatment of non-Small-Cell lung cancer. N. Engl. J. Med. 2015.
16. Gettinger S.N., Horn L., Gandhi L., Spigel D.R., Antonia S.J., Rizvi N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 2015: JCO 2014, 58:3708.
17. Gettinger S.N., Hellmann M.D., Shepherd F.A., Antonia S.J., Brahmer J.R., Chow L.Q.M., et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. ASCO Annual Meeting Proceedings 2015.
18. Group NM-aC Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010, 375(9722):1267-1277.
19. Gulley J.L., Spigel D., Kelly K., Chandler J.C., Rajan A., Hassan R., et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. ASCO Annual Meeting Proceedings 2015.
20. Herbst R.S., Baas P., Kim D.-W., Felip E., Pérez-Gracia J.L., Han J.-Y., et al. Pembrolizumab versus docetaxel for previously treated PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016.
21. Higgs B., Robbins P., Blake-Haskins J., Zhu W., Morehouse C., Brohawn P., et al. High tumoral IFN gamma mRNA, PD-L1 protein, and combined IFN gamma mRNA/PD -L1 protein expression associates with response to durvalumab (anti-PD -L1) monotherapy in NSCLC patients. Eur. J. Cancer 2015, (ELSEVIER SCI LTD THE BOULEVARD, LANGFORD, LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND).
22. Horn L., Spigel D.R., Gettinger S.N., Antonia S.J., Gordon M.S., Herbst R.S., et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. ASCO Annual Meeting Proceedings 2015.
23. Ilie M., Long-Mira E., Bence C., Butori C., Lassalle S., Bouhlel L., et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann. Oncol. 2015.
24. Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 2013, 94(1):25-39.
25. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control. Clin. Trials 1996, 17(1):1-12.
26. Marino P., Preatoni A., Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995, 76(4):593-601.
27. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009, 151(4):264-269.
28. Rizvi N.A., Mazières J., Planchard D., Stinchcombe T.E., Dy G.K., Antonia S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015, 16(3):257-265.
29. Silvestri G.A., Gonzalez A.V., Jantz M.A., Margolis M.L., Gould M.K., Tanoue L.T., et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer: American College of Chest Physicians evidence-based clinical practice guidelines. Chest J. 2013, 143(Suppl 5). e211S-e50S.
30. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20(19):5064-5074.
31. Thun M.J., Hannan L.M., Adams-Campbell L.L., Boffetta P., Buring J.E., Feskanich D., et al. Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med. 2008, 5(9):e185.
32. Vansteenkiste J., Fehrenbacher L., Spira A., Mazieres J., Park K., Smith D., et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). Eur. J. Cancer 2015, X5. (ELSEVIER SCI LTD THE BOULEVARD, LANGFORD, LANE, KIDLINGTON, OXFORD O 1GB, OXON, ENGLAND).
33. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014, 15(1):69-77.